- Home
- COEP vs VNRX Comparison
COEP vs VNRX Comparison
Compare COEP & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- VNRX
- Stock Information
- Founded
- COEP 2017
- VNRX N/A
- Country
- COEP United States
- VNRX United States
- Employees
- COEP N/A
- VNRX N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- COEP Health Care
- VNRX Health Care
- Exchange
- COEP Nasdaq
- VNRX Nasdaq
- Market Cap
- COEP 86.0M
- VNRX 69.7M
- IPO Year
- COEP N/A
- VNRX N/A
- Fundamental
- Price
- COEP $15.29
- VNRX N/A
- Analyst Decision
- COEP
- VNRX Strong Buy
- Analyst Count
- COEP 0
- VNRX 4
- Target Price
- COEP N/A
- VNRX $3.50
- AVG Volume (30 Days)
- COEP 66.5K
- VNRX 431.9K
- Earning Date
- COEP 11-12-2025
- VNRX 11-13-2025
- Dividend Yield
- COEP N/A
- VNRX N/A
- EPS Growth
- COEP N/A
- VNRX N/A
- EPS
- COEP N/A
- VNRX N/A
- Revenue
- COEP $263,555.00
- VNRX $1,319,252.00
- Revenue This Year
- COEP N/A
- VNRX $324.32
- Revenue Next Year
- COEP N/A
- VNRX $247.82
- P/E Ratio
- COEP N/A
- VNRX N/A
- Revenue Growth
- COEP N/A
- VNRX 35.10
- 52 Week Low
- COEP $2.31
- VNRX $0.40
- 52 Week High
- COEP $19.19
- VNRX $0.94
- Technical
- Relative Strength Index (RSI)
- COEP 49.85
- VNRX 27.56
- Support Level
- COEP $14.90
- VNRX $0.63
- Resistance Level
- COEP $16.17
- VNRX $0.67
- Average True Range (ATR)
- COEP 1.17
- VNRX 0.04
- MACD
- COEP -0.30
- VNRX -0.02
- Stochastic Oscillator
- COEP 11.94
- VNRX 4.90
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.